Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces Enterprise 3D Modeling Deal With AI Revenue Driving Growth (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. It is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.


NDAQ:XAIR - Post by User

Beyond Air Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Aug 30, 2021 7:48am
180 Views
Post# 33780658

BEYOND AIR: STRONG UPCOMING CATALYSTS MAKE THIS A MUST WATCH

BEYOND AIR: STRONG UPCOMING CATALYSTS MAKE THIS A MUST WATCH
Beyond Air (NASDAQ:XAIR) is a clinical-stage biopharmaceutical and medical device company that uses a proprietary technology to produce nitric oxide from ambient air through its LungFit System.
 
The Company has major upcoming catalysts that include the US FDA approval of LungFit:registered: PH ventilator compatible and interim data readouts from Acute viral pneumonia (including COVID19) and Nontuberculous mycobacteria (NTM) lung infection. The Company intends to launch e first in human studies in Multiple Solid Tumors by the end of 2021.
 
The Company's breakthrough technology can be a potential disruptor in the delivery of Nitric Oxide!
 
Read on to find out more!

Learn more
 
https://www.aviseanalytics.com/beyond-air-strong-upcoming-catalysts-make-this-a-must-watch/
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities